Ultrasensitive Quantification of Monoclonal Antibody

Significance of the topic

Monoclonal antibodies (mAbs) are a rapidly expanding class of therapeutics with growing importance in clinical care and drug development. Sensitive and specific quantification of mAbs at very low concentrations is critical for pharmacokinetics, biomarker research, bioanalysis in early drug discovery, and immunogenicity studies. Methods that combine high sensitivity with structural specificity and broad dynamic range enable more accurate monitoring of therapeutic exposure and facilitate decision-making across development stages.

Objectives and study overview

This application note presents a nanoflow LC–MS/MS workflow optimized for ultrasensitive quantification of mAbs using surrogate peptides produced by enzymatic digestion. Using trastuzumab as an example, the study demonstrates method sensitivity, linearity, and comparative performance versus standard analytical LC/MS approaches. The goal was to deliver a ready-to-implement, high-sensitivity platform that requires minimal additional method development for other human IgG-based therapeutics.

Methodology

The quantification strategy is based on bottom-up proteomics: trastuzumab was reduced, alkylated, and digested with sequencing-grade trypsin to release signature peptides. Key procedural points:

• Sample digestion: trastuzumab (10 µg) in 50 mM ammonium bicarbonate; reduction with dithiothreitol (10 mM) at 60 °C for 1 h; alkylation with iodoacetamide (10 mM) at room temperature in the dark for 30 min; trypsin (0.5 µg) digestion at 60 °C for 2 h with shaking.
• Quench/acidification: digestion stopped by acidification with 1% formic acid to produce an analyte-ready solution.
• Sample loading: digests were serially diluted down to 0.02 ng/mL and loaded onto Evotip trap devices using a conditioned-wash protocol to concentrate and desalting prior to nano-LC injection.
• Target peptide: ALPAPIEK, a conserved IgG-derived surrogate peptide shared by human IgG isoforms, was used for quantification by multiple reaction monitoring (MRM).

Instrumentation used

The workflow combines low-flow separation and a highly sensitive triple-quadrupole MS setup to maximize signal for low-abundance peptides. Instruments and consumables used:

• Evosep One LC system (Evosep) running the Whisper Zoom 40 SPD method.
• IonOpticks Aurora Elite XT C18 nano-column (15 cm × 75 µm id, 1.7 µm) with column heater; flow rate 200 nL/min; mobile phases A: water + 0.1% FA, B: acetonitrile + 0.1% FA; total run ≈33 min.
• Newomics UniESI ion source adapted for Agilent MS to improve nanoelectrospray stability and ion transmission.
• Agilent 6495D triple quadrupole mass spectrometer operated in positive ESI and MRM mode.
• Software: Agilent MassHunter Acquisition and MassHunter Quantitative Analysis (v12.0) for data processing and calibration.

Key LC–MS/MS parameters

Representative mass-spectrometry settings and MRM transitions used for peptide ALPAPIEK are summarized below:

• Precursor m/z: 419.8.
• Product ions monitored: m/z 327.6 (CE 10), 486.3 (CE 15), 654.4 (CE 10).
• Ion source conditions: gas temperature ~120 °C, drying gas 11 L/min, capillary voltage 1,800 V; ion funnel tuned for large molecules.
• Data weighting for calibration: 1/x^2 linear fit in MassHunter Quant.

Results and discussion

Method performance highlights and comparative findings:

• Sensitivity: the optimized nano-LC/TQ workflow achieved a lower limit of quantification (LLOQ) of 0.02 ng/mL for trastuzumab digest (equivalent to an approximate on-column quantification limit of 0.4 pg using a 20 µL digest injection).
• Linearity and dynamic range: the calibration response was linear from 0.02 to 10 ng/mL using 1/x^2 weighting.
• Signal improvement versus analytical LC/MS: nano-LC workflow produced substantially larger peptide signal—reported as a ~68-fold larger peak area for 1 ng/mL digest—corresponding to an estimated ~50-fold sensitivity improvement relative to a conventional UHPLC/MS reference method.
• MRM optimization: selection of the ALPAPIEK peptide and tuning of collision energies and transitions provided robust, interference-resistant quantification suitable for IgG-based therapeutics.

These results illustrate that combining low flow nano-LC, a high-efficiency nanoelectrospray source, and a sensitive triple-quadrupole detector yields major gains in detectability for surrogate peptides, enabling quantification at sub-ng/mL concentrations with good linearity.

Benefits and practical applications of the method

The presented workflow offers several advantages for bioanalysis and drug development laboratories:

• Ultrasensitive quantification suitable for early PK studies, biomarker work, or situations with limited sample availability.
• High specificity through peptide-based MRM detection, reducing cross-reactivity issues inherent in ligand-binding assays.
• Minimal method development required to transfer the approach to other human IgG-based mAbs because the surrogate peptide is conserved across IgG subclasses.
• Sufficient throughput for targeted quantitation using Evotip sample handling combined with relatively short nano-LC methods.

Future trends and applications

Expected directions and opportunities for expansion of this approach include:

• Extension to multiplexed quantitation of multiple therapeutic antibodies or their variants in a single run by expanding the MRM panel.
• Integration with stable isotope-labeled peptide standards for absolute quantification and improved inter-lab comparability.
• Application to intact or middle-down approaches when structural variant information (e.g., glycoforms, truncated species) is required alongside quantitation.
• Adoption of improved nanoelectrospray interfaces and ion transmission optics to push limits of detection further while maintaining robustness for routine use.

Conclusion

The combined Evosep Whisper nano-LC method, IonOpticks column, Newomics UniESI source, and Agilent 6495D triple-quadrupole MS provide an optimized platform for ultrasensitive surrogate-peptide quantification of monoclonal antibodies. The workflow reliably quantified trastuzumab down to 0.02 ng/mL with linear response to 10 ng/mL, demonstrating substantial sensitivity gains over standard analytical LC/MS. Its general applicability to IgG therapeutics and modest method-development burden make it a practical option for bioanalysis in drug discovery and development.

Reference

1. Monoclonal Antibody Therapeutics Market Size to Reach USD 919.06 Billion by 2033, BioSpace. Market analysis source (2026).
2. Jenkins, R.; Duggan, J. X.; Aubry, A.-F.; Zeng, J.; Lee, J. W.; Cojocaru, L.; Dufield, D.; Garofolo, F.; Kaur, S.; Schultz, G. A.; et al. Recommendations for Validation of LC–MS/MS Bioanalytical Methods for Protein Biotherapeutics. AAPS Journal 2015, 17(1), 1–16. DOI: 10.1208/s12248-014-9685-5.
3. Boekhout, A. H.; Beijnen, J. H.; Schellens, J. H. M. Trastuzumab. Oncologist 2011, 16(6), 800–810. DOI: 10.1634/theoncologist.2010-0035.